Air Liquide announced today that it has entered into exclusive negotiations with EQT AB, a global investment organization with strong roots and base in Germany, for the potential sale of Schülke & Mayr GmbH. EQT is a growth-focused investor with an impressive track-record of developing strong companies in the German healthcare sector.
After completion of the possible acquisition, EQT will support Schülke & Mayr GmbH in its continuous development and growth based on common and sustainable values. This is the way EQT creates value to a broad set of stakeholders: investors, portfolio companies and their employees, and society at large. The transaction is subject to the final and definitive agreement between the parties, and will be carried out in the framework of the relevant social processes and ongoing dialogue with the employee representatives’ bodies. Furthermore, the transaction will be subject to antitrust and foreign investissements clearances.
With regard to the current crisis situation caused by the COVID-19 pandemic, we will continue to provide our customers with the best possible support and supply them with the required products. Thanks to the measures already implemented to increase our production, we were able to more than double the production output of the most urgently needed products delivered in March. The entire schülke team is doing a great job in these challenging times and is highly motivated in the fight against the COVID-19 pandemic.
schülke is in direct contact and exchange with the Federal Ministry of Health and political decision makers, also together with our industry associations, in order to further improve the supply of the healthcare system, ensure raw materials and its customers with necessary disinfectants to fight the crisis.
About Schülke & Mayr GmbH
Schülke & Mayr GmbH, headquartered in Germany, has been one of the leading manufacturers in the field of infection prevention and hygiene for more than 130 years. schülke develops, produces and distributes antiseptics for wound care, disinfectants, medical and cosmetic skin care products and preservatives. schülke offers its customers innovative products, technologies and services in its core business areas: Healthcare, Industrial Hygiene, Personal Care and Over the Counter (OTC). schülke's mission is to protect lives worldwide, and in doing so, schülke actively contributes to patient safety. Today, the company employs approximately 1,300 people worldwide and sells its products in more than 100 countries and is represented by 20 subsidiaries. schülke operates three production sites in Germany (schülke), France (Bioxal) and Brazil (Vic Pharma).